Kadimastem Ltd
Built from real-time financials and updated daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a KMSTF research report →
Companywww.kadimastem.com
Kadimastem Ltd, a biopharmaceutical company, develops regenerative medicine therapies based on cells derived from human embryonic stem cells to treat neuro-degenerative diseases. Its products in pipeline include AstroRx, a clinical grade human astrocytes that is in Phase 1/2a clinical trial for the treatment of amyotrophic lateral sclerosis and other neurodegenerative diseases; and IsletRx, a clinical grade pancreatic islet cell therapy treatment for diabetes. The company was founded in 2008 and is based in Ness Ziona, Israel.
- CEO
- Ronen Twito
- IPO
- 2021
- Employees
- 11
- HQ
- Ness Ziona, IL
Price Chart
Valuation
- Market Cap
- $9.50M
- P/E
- -2.35
- P/S
- 0.00
- P/B
- -0.00
- EV/EBITDA
- -20321.33
- Div Yield
- 0.00%
Profitability
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- 0.12%
- ROIC
- 10.67%
Growth & Income
- Revenue
- $0 · 0.00%
- Net Income
- $-7,287,196 · 39.52%
- EPS
- $-1.74 · 56.13%
- Op Income
- $-1,812,742
- FCF YoY
- 75.01%
Performance & Tape
- 52W High
- $9.07
- 52W Low
- $0.64
- 50D MA
- $6.79
- 200D MA
- $7.25
- Beta
- 0.57
- Avg Volume
- 40.24K
Get TickerSpark's AI analysis on KMSTF
Pro members can request AI-generated analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →30-day money-back guarantee · cancel anytime
Our KMSTF Coverage
We haven't published any research on KMSTF yet
For a full analyst-grade research report — grades, price targets, full financials, chart analysis — generate one on demand.
Generate KMSTF Report →